Press Release: Strong 2021 sales and business EPS growth enabling increased investment in R&D
February 04, 2022 01:30 ET
|
Sanofi - Aventis Groupe
Strong 2021 sales and business EPS(1) growth enabling increased investment in R&D Paris, February 4, 2022 Q4 2021 sales growth of 4.1% and business EPS(1) growth of 9.8% at CER Specialty...
Press Release: Strong 2021 sales and business EPS growth enabling increased investment in R&D
February 04, 2022 01:30 ET
|
Sanofi - Aventis Groupe
Strong 2021 sales and business EPS(1) growth enabling increased investment in R&D Paris, February 4, 2022 Q4 2021 sales growth of 4.1% and business EPS(1) growth of 9.8% at CER Specialty...
Sanofi va acquérir Amunix pour son portefeuille en immuno-oncologie avec une nouvelle génération d’agents biologiques à activation conditionnelle
December 20, 2021 23:30 ET
|
Sanofi - Aventis Groupe
Sanofi va acquérir Amunix pour son portefeuille en immuno-oncologie avec une nouvelle génération d’agents biologiques à activation conditionnelle Une opération qui apporte un portefeuille...
Sanofi to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics
December 20, 2021 23:30 ET
|
Sanofi - Aventis Groupe
Sanofi to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics Adds promising pipeline of T-cell engagers and cytokine therapies with lead candidate...
ORIC Pharmaceuticals Appoints Angie You, Ph.D., to its Board of Directors
November 10, 2021 16:15 ET
|
ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...
Amunix Presents Preclinical Data on Its XPAT T Cell Engager Platform at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
October 07, 2021 09:00 ET
|
Amunix Pharmaceuticals, Inc.
AMX-818, an HER2-targeted T cell engager (TCE), is the lead program in Amunix’s XPAT® (XTENylated Protease-Activated TCE) platform designed to improve the therapeutic index of TCEs for the treatment...
Hangzhou Chance Pharmaceuticals Appoints Guobao Zhao as Senior Vice President
September 29, 2021 20:59 ET
|
Hangzhou Chance Pharma
HANGZHOU, China, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Hangzhou Chance Pharmaceuticals (“Chance”), a clinical-stage biotechnology company focusing on discovering, developing, and commercializing...
Amunix Appoints Industry Veteran, Frank Watanabe, to its Board of Directors
June 23, 2021 07:00 ET
|
Amunix Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), an immuno-oncology company leveraging its proprietary, clinically validated Pro-XTEN...
Lipodystrophy Pipeline | A Clinical Trials Analysis Report | DelveInsight
June 09, 2021 20:00 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, June 09, 2021 (GLOBE NEWSWIRE) -- Lipodystrophy Pipeline | A Clinical Trials Analysis Report | DelveInsight The companies with their Lipodystrophy drug candidates in the most...
Amunix Expands its Board of Directors with the Appointment of Industry Veteran, Ciara Kennedy, Ph.D., M.B.A.
May 13, 2021 07:00 ET
|
Amunix Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), an immuno-oncology company leveraging its proprietary, clinically validated Pro-XTEN technology...